Related Experiment Video
Updated: Aug 19, 2025

07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.7K
A Multicenter Virtual Multidisciplinary Sarcoma Case Conference Improves Outcome for a Rare Soft Tissue Sarcoma
Amber L Chang1, Hyunjee V Kwak2, Minggui Pan3
1Department of Biology, UC Davis, Davis, CA, USA.
The American Surgeon
|November 28, 2022
Summary
The virtual multidisciplinary sarcoma case conference (VMSCC) significantly improved outcomes for dermatofibrosarcoma protuberans (DFSP) patients. Post-VMSCC implementation, positive surgical margins and local recurrence rates decreased substantially.
Area of Science:
- Oncology
- Surgical Pathology
- Medical Informatics
Background:
- Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer.
- Optimizing DFSP patient outcomes requires multidisciplinary care coordination.
- Virtual multidisciplinary sarcoma case conferences (VMSCC) offer a novel approach to care coordination.
Purpose of the Study:
- To evaluate the impact of VMSCC implementation on DFSP patient outcomes.
- To compare surgical margin status and disease-free survival (DFS) before and after VMSCC adoption.
- To assess changes in local recurrence rates for DFSP patients.
Main Methods:
- Retrospective analysis of two DFSP patient cohorts (2010-2015 and 2016-2020).
- Comparison of margin status and DFS using Kaplan-Meier curves and Cox regression.
- VMSCC implementation occurred between the two study periods at Kaiser Permanente Northern California.
Main Results:
- No significant demographic or tumor characteristic differences between cohorts.
- A significant reduction in positive surgical margins from 6.5% to 0.8%.
- A significant decrease in local recurrence rates from 6.3% to 0% post-VMSCC.
Conclusions:
- VMSCC implementation is associated with improved surgical and oncologic outcomes for DFSP.
- VMSCC facilitates better management of complex sarcoma cases.
- Virtual multidisciplinary conferences represent a valuable tool in optimizing cancer care delivery.

